Copyright © Queen's Printer,

Victoria, British Columbia, Canada

Licence

Disclaimer

Volume 58, No. 18

180/2015

The British Columbia Gazette,

Part II

October 6, 2015

B.C. Reg. 180/2015 , deposited September 28, 2015, under the PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [section 22 (2.3)]. Ministerial Order M300/2015, dated August 25, 2015.

I, Lynn Stevenson, Associate Deputy Minister, Ministry of Health, order that the board of the College of Pharmacists of British Columbia may, on or after the date of this Order, deposit with the Registrar of Regulations the amendments to the Drug Schedules Regulation, B.C. Reg. 9/98, that are set out in the

schedule to the attached resolution of the board dated April 17, 2015.

— L. STEVENSON, Associate Deputy Minister, Ministry of Health .

Resolution of the Board of the College of Pharmacists of British Columbia made the 17th day of April, 2015, at Vancouver, British Columbia.

RESOLVED THAT, in accordance with the authority established in

section 22 (1) of the Pharmacy Operations and Drug Scheduling Act , and subject to filing with the Minister as required by

section 22 (2) of the Pharmacy Operations and Drug Scheduling Act , the board amend the Drug Schedules Regulation, B.C. Reg. 9/98, as set out in the

schedule attached to this resolution.

Certified a true copy

— Suzanne Solven, Deputy Registrar .

Schedule

1 The Drug Schedules Regulation, B.C. Reg. 9/98, is amended in the Schedules

(

a) by striking out the following:

3 Bisacodyl and its salts

1 Diclofenac and its salts, except when sold as a single medicinal ingredient in a concentration equivalent of 1% or less diclofenac in preparations for topical use on the skin

1 Minoxidil (except in topical solution in concentrations of 2% or less)

3 Minoxidil topical solution in concentrations of 2% or less

1 Omeprazole and its salts , and

(

b) by adding the following:

3 Bisacodyl and its salts except when sold in

(

a) concentrations of 5 mg or less per oral dosage unit or 10 mg or less per rectal dosage unit/suppository, and

(

b) package sizes containing no more than 50 mg of bisacodyl

1 Diclofenac and its salts, including but not limited to diclofenac diethylamine, diclofenac sodium and diclofenac potassium, except when sold as a single medicinal ingredient for topical use on the skin in a concentration equivalent to 2% or less of diclofenac for not more than 7 days

2 Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,

(

a) in concentrations greater than 1.16% and less than or equal to 2.32%, and

(

b) in package sizes containing greater than 2.6 g of diclofenac diethylamine

3 Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days,

(

a) in concentrations greater than 1.16% and less than or equal to 2.32%, and

(

b) in package sizes containing no more than 2.6 g of diclofenac diethylamine

3 Dimeticone 100 cSt solution 50% w/w for topical use in the treatment of head lice

1 Minoxidil except when sold in preparations for topical use in concentrations of 5% or less

3 Minoxidil foam for topical use in concentrations of 5% or less for androgenetic alopecia (male or female pattern baldness or hair loss)

3 Minoxidil in solutions for topical use in concentrations of 2% or less

1 Omeprazole or its salts except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20mg in package sizes of no more than 280mg of omeprazole

2 Omeprazole or its salts when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of omeprazole

1 Pancreatic extracts when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

1 Pancreatin when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

1 Pancrelipase when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency .

Copyright © 2016: Queen's Printer, Victoria, British Columbia, Canada